ArticleArthritis care & research2012
Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy.
Article in Arthritis care & research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 56 citations in OpenAlex.
- Higher bacterial DNAemia can affect the impact of a polyphenol-rich dietary pattern on biomarkers of intestinal permeability and cardiovascular risk in older subjects.European journal of nutrition · 2022Trial
- Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.Arthritis and rheumatism · 2013Trial
- Residual Traditional Risk in Non-Traditional Atherosclerotic Diseases.International journal of molecular sciences · 2025Review
- The association between remnant cholesterol and rheumatoid arthritis: insights from a large population study.Lipids in health and disease · 2024Article
- Impact of anti-tumor necrosis factor treatment on lipid profiles in Korean patients with ankylosing spondylitis.Journal of rheumatic diseases · 2024Article
- Methotrexate conjugated gold nanoparticles improve rheumatoid vascular dysfunction in rat adjuvant-induced arthritis: gold revival.Inflammopharmacology · 2023Article
- Tripterygium wilfordii glycosides ameliorates collagen-induced arthritis and aberrant lipid metabolism in rats.Frontiers in pharmacology · 2022Article
- Cardiovascular Risk in Rheumatoid Arthritis: Literature Review.Oman medical journal · 2021Review
- Insights in the Role of Lipids, Oxidative Stress and Inflammation in Rheumatoid Arthritis Unveiled by New Trends in Lipidomic Investigations.Antioxidants (Basel, Switzerland) · 2021Review
- What methods are being used to create an evidence base on the use of laboratory tests to monitor long-term conditions in primary care? A scoping review.Family practice · 2020Article
- High-Density Lipoprotein Modifications: A Pathological Consequence or Cause of Disease Progression?Biomedicines · 2020Review
- Immunomodulatory effects of berberine on the inflamed joint reveal new therapeutic targets for rheumatoid arthritis management.Journal of cellular and molecular medicine · 2020Review
- Inflammation as a Therapeutic Target in Atherosclerosis.Journal of clinical medicine · 2019Review
- Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications.BMJ (Clinical research ed.) · 2018Review
- Effects of Treatment with Adalimumab on Blood Lipid Levels and Atherosclerosis in Patients with Rheumatoid Arthritis.Current therapeutic research, clinical and experimental · 2018Article
- Effects of anti-TNF-α treatment on lipid profile in rheumatic diseases: an analytical cohort study.Arthritis research & therapy · 2016Article
- Lipid and Metabolic Changes in Rheumatoid Arthritis.Current rheumatology reports · 2015Review
- Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis.BMC medical genomics · 2015Article
- Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study.Arthritis care & research · 2015Observational
- Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib.Arthritis & rheumatology (Hoboken, N.J.) · 2015Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo investigate the frequency of lipid testing in clinical practice and to explore the relationship between rheumatoid arthritis (RA), dyslipidemia, and other cardiovascular (CV) risk factors with RA treatment.
methodsPatients in this retrospective database study were ages ≥18 years and had ≥2 physician diagnoses for RA or osteoarthritis (OA; comparator group) between March 2004 and March 2008. Outcomes of interest included the percentage of RA and OA patients receiving lipid tests, lipid profiles (total cholesterol, low-density lipoprotein [LDL] cholesterol, and high-density lipoprotein [HDL] cholesterol) of RA versus OA patients, and lipid profiles of RA patients before and after initiation with a tumor necrosis factor (TNF) inhibitor. We used multivariable regression to control potential confounders between the cohorts.
resultsOver a median ≥2-year followup, fewer RA patients than OA patients had ≥1 lipid test (62.0% [95% confidence interval (95% CI) 61.5-62.5] versus 69.8% [95% CI 69.5-70.1]). Mean total cholesterol and LDL cholesterol were each 4 mg/dl lower in the RA cohort (P < 0.0001); HDL cholesterol was similar between the cohorts. Across the RA cohort, 25.2% of patients had suboptimal LDL cholesterol levels (≥130 mg/dl). Among RA patients not receiving lipid-lowering therapy who initiated TNF inhibitor therapy (n = 96), mean total cholesterol and LDL cholesterol increased by 5.4 and 4.0 mg/dl, respectively.
conclusionPatients with RA were less likely to be tested for hyperlipidemia and had more favorable lipid profiles than patients with OA. TNF inhibitor therapy modestly increased all lipid parameters. Additional studies are needed to determine the effect of traditional CV risk factors and inflammation and the impact of biologic agents on CV outcomes in RA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.